Article Text

Download PDFPDF

LP-149 Latin-American systemic lupus erythematosus clusters
  1. Rosana Quintana1,
  2. Romina Nieto1,
  3. Guillermo J Pons-Estel1,
  4. José Gómez Puerta1,
  5. Guillermina Harvey1,
  6. Marina Scolnik1,
  7. Nidia Meras1,
  8. Cintia Otaduy1,
  9. Elisa Novati1,
  10. Valeria Arturi1,
  11. María Emilia Sattler1,
  12. Luciana González Lucero1,
  13. Wilfredo Patiño Grageda1,
  14. Nicolás Pérez1,
  15. Cecilia Pisoni1,
  16. Ana Carolina De Oliveirae Silva Montaton1,
  17. Odirlei Andre Monticielo1,
  18. Angela Duarte1,
  19. Francinne Machado Ribeiro1,
  20. Emily Figueiredo Neves Yuki1,
  21. Edgard Torres Dos Reis-Neto1,
  22. Iris Guerra1,
  23. Milena Mimica Davet1,
  24. Gustavo Aroca Martínez1,
  25. Gabriel J Tobón1,
  26. Gerardo Quintana-Lopez1,
  27. Andrés Cadena Bonfanti1,
  28. Mario Moreno Álvarez1,
  29. Miguel Angel Saavedra Salinas1,
  30. Margarita Portela Hernández1,
  31. Hilda Fragoso Loyo1,
  32. Luis H Silveira1,
  33. Ignacio García valladares1,
  34. Carlos Abud Mendoza1,
  35. Jorge A Esquivel-Valerio1,
  36. Maria Teresa Martinez1,
  37. Margarita Duarte1,
  38. Claudia Selene Mora Trujillo1,
  39. Manuel Ugarte-Gil1,
  40. S Ernesto1,
  41. Roberto Muñoz louis1,
  42. Ricardo Robaina1,
  43. Vicente Juarez1,
  44. Gonzalo Silveira1,
  45. Eduardo Borba1,
  46. Luis J Catoggio1,
  47. Graciela S Alarcón1,
  48. Federico Zazzetti2,
  49. Ashley Orillion3,
  50. Urbano Sbarigia4 and
  51. Bernardo A Pons-Estel1
  1. 1Rheumatology, GLADEL (Latin American Group for the Study of Lupus), Argentina
  2. 2Rheumatology, Janssen Pharmaceutical Companies of Johnson and Johnson, USA
  3. 3Rheumatology, Janssen Pharmaceutical Companies of Johnson and Johnson, USA
  4. 4Rheumatology, Janssen Pharmaceutical, Belgium


Background Systemic lupus erythematosus (SLE) is heterogeneous autoimmune disease. Identification of patient clusters may be useful for the management of the disease. The aim of this study is to describe different SLE clusters according to sociodemographic, clinical and serological characteristics.

Methods GLADEL 2.0 is an ongoing Latin-American observational cohort initiated in 2019. Variables chosen at cohort entry to stratify patients and construct clusters were selected from sociodemographic and cumulative clinical and serological variables. Hierarchical cluster analyses were performed by the Ward method on a distance matrix using the Gower’s method.

Results A total of 560 SLE patients were included in this analysis. Three clusters were identified. Cluster 1 (n=269) was characterized by more cutaneous, articular, renal and serosal involvement; serological manifestation was positive anti-dsDNA. Cluster 2 (n=194) was represented by patients who rarely had renal involvement and the most frequent clinical manifestations were cutaneous and hematological; the most frequent serological manifestations were the presence of antiphospholipid antibodies (aPLs). Cluster 3 (n=97) was characterized by a lower frequency of clinical and serological involvements, with the exception of neurological domain. Clusters 1 and 2 share hematologic manifestations and hypocomplementemia (table 1).

Conclusions In this cohort, three clusters were identified. Cluster 1 patients were characterized by renal, articular, cutaneous and serositis involvement, anti-dsDNA antibodies and hypocomplementemia, Cluster 2 patients were characterized by hematologic, cutaneous involvement, aPLs and hypocomplementemia. Cluster 3 patients presented fewer serological findings but a higher frequency of neurological involvement. Follow up of these patients will allow for elucidation of relationship of these clusters with SLE outcomes.

Abstract LP-149 Table 1

Clustering of GLADEL 2.0 SLE patients based on sociodemographic, serological and clinical characteristics

  • Systemic lupus erythematosus
  • Registries
  • Autoantibodies

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See:

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.